SG Americas Securities
SMMT icon

SG Americas Securities’s Summit Therapeutics SMMT Stock Holding History

SG Americas Securities’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-53,523
Closed -$1.01M – 3642
2026
Q1 		$1.01M Buy
53,523
+37,934
+243% +$613K ﹤0.01% 1751
2025
Q4 		$273K Buy
15,589
+10,472
+205% +$197K ﹤0.01% 2798
2025
Q3 		$106K Buy
+5,117
New +$124K ﹤0.01% 3059
2025
Q1 		– Sell
-13,169
Closed -$235K – 3741
2024
Q4 		$235K Sell
13,169
-19,587
-60% -$380K ﹤0.01% 2008
2024
Q3 		$717K Buy
+32,756
New +$458K ﹤0.01% 1364
2022
Q1 		– Sell
-12,671
Closed -$34K – 3388
2021
Q4 		$34K Sell
12,671
-10,529
-45% -$50.6K ﹤0.01% 3226
2021
Q3 		$116K Buy
+23,200
New +$166K ﹤0.01% 3594

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

SG Americas Securities's SMMT Position: Q2 2026 in Review

SG Americas Securities sold out of Summit Therapeutics (SMMT) in Q2 2026, closing a stake of 53,523 shares — an estimated $1.01M sold.

SG Americas Securities first reported a position in SMMT in Q3 2021 and held it in 7 quarters. The position peaked at $1.01M in Q1 2026. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • SG Americas Securities reported no remaining Summit Therapeutics position as of Q2 2026 after selling out during the quarter.
  • SG Americas Securities sold 53,523 Summit Therapeutics shares in Q2 2026, an estimated $1.01M.
  • SG Americas Securities first reported a position in Summit Therapeutics in Q3 2021 and held it in 7 quarters.
  • SG Americas Securities's Summit Therapeutics position peaked at $1.01M in Q1 2026.
  • 243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.